64Cu-SAR-bisPSMA

DRUG7 trials

Sponsors

Clarity Pharmaceuticals Ltd, Luke Nordquist, MD, St Vincent's Hospital, Sydney

Conditions

Biochemical Recurrence of Malignant Neoplasm of ProstateCryotherapyProstate CancerProstate Cancer (Post Prostatectomy)Prostate Cancer Patients Treated by RadiotherapyProstate Cancer Patients Who Have Brachytherapy Seed ImplantProstate Cancer Patients With Detectable PSA Following ProstatectomyProstate Cancer Recurrent

Phase 1

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

CompletedNCT04839367

Clarity Pharmaceuticals LtdProstatic Neoplasms

Start: 2021-07-13End: 2022-10-19Updated: 2023-01-17

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

RecruitingNCT04868604

Clarity Pharmaceuticals LtdProstatic Neoplasms, Castration-Resistant

Start: 2021-08-11End: 2026-09-01Target: 54Updated: 2026-05-06

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

CompletedNCT05249127

Clarity Pharmaceuticals LtdBiochemical Recurrence of Malignant Neoplasm of Prostate

Start: 2022-04-11End: 2023-08-08Updated: 2024-10-01

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Luke Nordquist, MDProstate Cancer

Start: 2022-03-28End: 2023-09-30Target: 150Updated: 2022-03-18

Phase 2

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

CompletedNCT06907641

St Vincent's Hospital, SydneyProstate Cancer (Post Prostatectomy)

Start: 2024-11-21End: 2025-09-03Updated: 2026-08-14

Phase 3

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

RecruitingNCT06056830

Clarity Pharmaceuticals LtdProstate Cancer, Prostatic Neoplasms

Start: 2023-12-21End: 2026-09-01Target: 383Updated: 2026-09-11

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Active, not recruitingNCT06970847

Clarity Pharmaceuticals LtdCryotherapy, Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy +3

Start: 2025-05-16End: 2026-12-31Target: 220Updated: 2026-05-14

Related Papers

Optimization of Administered Activity for 64Cu-SAR-bisPSMA PET Imaging in Primary Prostate Cancer: Results from a Phase I Retrospective Study (PROPELLER Sub-study)

World Journal of Nuclear Medicine2026-06-23

AMPLIFY: A phase 3 study of <sup>64</sup> Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.

Journal of Clinical Oncology2026-05-28

COBRA: Assessment of the efficacy of <sup>64</sup> Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.

Journal of Clinical Oncology2025-05-28

SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of <sup>67</sup> Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.

Journal of Clinical Oncology2025-05-28

COBRA: Assessment of the efficacy of <sup>64</sup> Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.

Journal of Clinical Oncology2025-02-10

CLARIFY: Positron emission tomography using <sup>64</sup> Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy—A phase 3 diagnostic performance study.

Journal of Clinical Oncology2025-02-10

COBRA: Assessment of safety and efficacy of <sup>64</sup>Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.

Journal of Clinical Oncology2024-06-012 citations

SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of <sup>67</sup>Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.

Journal of Clinical Oncology2024-06-012 citations

CLARIFY: Positron emission tomography using <sup>64</sup>Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study).

Journal of Clinical Oncology2024-06-011 citations

SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of <sup>67</sup>Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.

Journal of Clinical Oncology2024-01-292 citations

<sup>64</sup>Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.

Journal of Clinical Oncology2023-06-014 citations

Positron emission tomography of patients with confirmed prostate cancer using <sup>64</sup>Cu-SAR-bisPSMA.

Journal of Clinical Oncology2023-02-20